Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Information Management Services Inc, Calverton, Maryland.
Westat Inc, Rockville, Maryland.
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
- Published Article
Wiley (John Wiley & Sons)
- Publication Date
Feb 15, 2017
The implied decimal error rate was only 1.93% of all cases in the current validation study, with a meaningful error rate of 5.81%. The reasons for the lower error rate in SEER are likely due to ongoing and rigorous quality control and visual editing processes by the central registries. The SEER program currently is reviewing and correcting PSA values back to 2004 and will re-release these data in the public use research file. Cancer 2017;123:697-703. © 2016 American Cancer Society.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/27783399